Alqarni Abdullah, Hosmani Jagadish, Meer Rayan Mohammedfarooq, Alqarni Abdulwahab, Alumudh Abdullah, Perumal Elumalai, Karobari Mohmed Isaqali
Chairman of Department of Diagnostic Sciences & Oral Biology, College of Dentistry, King Khalid University, Abha, Kingdom of Saudi Arabia.
Department of Diagnostic Sciences and Oral Biology, College of Dentistry, King Khalid University, Abha, Kingdom of Saudi Arabia.
BMC Complement Med Ther. 2025 Mar 8;25(1):98. doi: 10.1186/s12906-025-04833-x.
Shilajit is a pale-brown to blackish-brown fluid that varies in consistency and is released from rock layers in various mountain ranges across the world. For thousands of years, traditional medical systems in several nations have included shilajit in one form or another as a rejuvenator and adaptogen. Numerous medicinal qualities have been attributed to it, several of which have been confirmed by contemporary scientific analysis. This in vitro study was established to investigate the effect of shilajit on human Periodontal ligament (hPDL) cell wound closure.
The cell viability was evaluated using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide tetrazolium reduction (MTT) test following a 24-hour exposure of shilajit. With the use of an inverted phase contrast microscope, morphological alterations were noted. Acridine orange/ethidium bromide dual labeling, to evaluate the apoptotic cell death in shilajit treated cells. An in vitro wound healing test was utilized to evaluate wound healing in wounded hPDL cell monolayers for 24 h in the presence or absence of shilajit. The Matrix metalloproteinases-2 and 9 (MMP-2 and MMP-9) in hPDL cells treated with shilajit were measured using the enzyme-linked immunosorbent assay (ELISA) technique, and real-time PCR was used to examine gene expression linked to wound healing and apoptosis.
Shilajit's cytotoxicity evaluation on hPDL cells showed that dosages as high as 3 mg/mL had no adverse effects and maintains the cell viability, suggesting a possible stimulatory effect on cell growth. Cell viability was reduced significantly (p < 0.05) by dosages more than 4 mg/mL, indicating cytotoxicity at higher concentrations. According to the scratch wound healing assay, shilajit administration at doses of 2 and 3 mg/mL accelerated wound healing and improved cell migration in hPDL cells. Shilajit promoted a controlled inflammatory response and supported periodontal ligament healing by upregulating the expression of genes involved in collagen synthesis, collagen type I alpha 1 chain (COL1A1) and pro-inflammatory cytokines, tumor necrosis factor alpha (TNF-α) and, interleukin-1-beta (IL-1β), according to real-time PCR data. In addition, Shilajit raised the protein levels of MMP2 and MMP9, two important enzymes involved in tissue remodeling. Shilajit-treated hPDL cells showed a substantial increase of cell proliferation and no discernible apoptotic activity.
Our research offers novel proof that shilajit promotes hPDL cell migration and proliferation, which in turn promotes wound closure. According to these results, Shilajit may improve tissue regeneration, accelerate wound healing, and encourage the growth of periodontal ligament cells.
希拉季特是一种浅棕色至深棕色的液体,其稠度各异,源自世界各地不同山脉的岩层。数千年来,多个国家的传统医学体系都以某种形式将希拉季特用作回春剂和适应原。它具有众多药用特性,其中一些已得到当代科学分析的证实。本体外研究旨在探讨希拉季特对人牙周膜(hPDL)细胞伤口闭合的影响。
在希拉季特暴露24小时后,使用3-(4,5-二甲基噻唑-2-基)-2,5-二苯基四氮唑溴盐还原(MTT)试验评估细胞活力。通过倒置相差显微镜观察形态学改变。使用吖啶橙/溴化乙锭双重染色评估希拉季特处理细胞中的凋亡细胞死亡。利用体外伤口愈合试验评估在有或无希拉季特存在的情况下,受伤的hPDL细胞单层在24小时内的伤口愈合情况。使用酶联免疫吸附测定(ELISA)技术测量希拉季特处理的hPDL细胞中的基质金属蛋白酶-2和9(MMP-2和MMP-9),并使用实时聚合酶链反应(PCR)检测与伤口愈合和凋亡相关的基因表达。
希拉季特对hPDL细胞的细胞毒性评估表明,高达3mg/mL的剂量没有不良影响,并维持细胞活力,表明对细胞生长可能有刺激作用。超过4mg/mL的剂量会显著降低细胞活力(p<0.05),表明在较高浓度下具有细胞毒性。根据划痕伤口愈合试验,2mg/mL和3mg/mL剂量的希拉季特给药可加速hPDL细胞的伤口愈合并改善细胞迁移。根据实时PCR数据,希拉季特通过上调参与胶原蛋白合成的基因、I型胶原蛋白α1链(COL1A1)以及促炎细胞因子、肿瘤坏死因子α(TNF-α)和白细胞介素-1-β(IL-1β)的表达,促进了可控的炎症反应并支持牙周膜愈合。此外,希拉季特提高了MMP2和MMP9这两种参与组织重塑的重要酶的蛋白质水平。希拉季特处理的hPDL细胞显示细胞增殖显著增加,且无明显凋亡活性。
我们的数据提供了新的证据,表明希拉季特促进hPDL细胞迁移和增殖,进而促进伤口闭合。根据这些结果,希拉季特可能改善组织再生,加速伤口愈合,并促进牙周膜细胞生长。